Indivior (NASDAQ:INDV) Upgraded by Barclays to Strong-Buy Rating

Barclays upgraded shares of Indivior (NASDAQ:INDV) to a strong-buy rating in a research note released on Thursday, MarketBeat Ratings reports.

Several other equities analysts have also issued reports on INDV. Weiss Ratings lowered shares of Indivior from a “hold (c+)” rating to a “hold (c)” rating in a report on Wednesday, May 6th. Zacks Research upgraded Indivior from a “hold” rating to a “strong-buy” rating in a report on Monday, March 16th. Two investment analysts have rated the stock with a Strong Buy rating, five have assigned a Buy rating and one has given a Hold rating to the stock. Based on data from MarketBeat.com, Indivior presently has a consensus rating of “Buy” and a consensus price target of $40.29.

Indivior Price Performance

Shares of NASDAQ:INDV opened at $38.28 on Thursday. The firm’s 50 day simple moving average is $36.06 and its 200 day simple moving average is $34.44. Indivior has a fifty-two week low of $13.45 and a fifty-two week high of $41.00. The company has a market capitalization of $4.67 billion, a price-to-earnings ratio of 19.63 and a beta of 0.88.

Indivior (NASDAQ:INDV) last issued its quarterly earnings data on Tuesday, March 31st. The company reported $0.96 earnings per share (EPS) for the quarter. Indivior had a net margin of 19.44% and a negative return on equity of 219.26%. The firm had revenue of $317.00 million during the quarter. Equities research analysts expect that Indivior will post 4.05 earnings per share for the current year.

Insiders Place Their Bets

In other Indivior news, CFO Ryan Preblick sold 36,000 shares of Indivior stock in a transaction that occurred on Monday, June 8th. The shares were sold at an average price of $37.70, for a total value of $1,357,200.00. Following the transaction, the chief financial officer owned 284,751 shares of the company’s stock, valued at approximately $10,735,112.70. The trade was a 11.22% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 0.74% of the company’s stock.

Institutional Investors Weigh In On Indivior

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Rockefeller Capital Management L.P. lifted its position in Indivior by 512.4% in the 4th quarter. Rockefeller Capital Management L.P. now owns 1,286 shares of the company’s stock valued at $46,000 after acquiring an additional 1,076 shares in the last quarter. Caitong International Asset Management Co. Ltd increased its holdings in Indivior by 72.7% during the 4th quarter. Caitong International Asset Management Co. Ltd now owns 1,093 shares of the company’s stock worth $39,000 after purchasing an additional 460 shares in the last quarter. Virtu Financial LLC acquired a new stake in shares of Indivior in the 4th quarter valued at about $344,000. Invesco Ltd. lifted its holdings in shares of Indivior by 274.6% in the fourth quarter. Invesco Ltd. now owns 286,689 shares of the company’s stock valued at $10,286,000 after purchasing an additional 210,150 shares in the last quarter. Finally, Mercer Global Advisors Inc. ADV acquired a new position in shares of Indivior during the fourth quarter worth about $274,000. 60.33% of the stock is currently owned by institutional investors and hedge funds.

About Indivior

Indivior plc is a specialty pharmaceutical company dedicated to developing and delivering treatments for addiction and related mental health disorders. The company’s portfolio centers on therapies designed to support individuals dealing with opioid dependence, alcohol use disorder and other behavioral health challenges. Its lead products include Suboxone® (buprenorphine and naloxone) sublingual film and Sublocade® (extended-release buprenorphine) injection, both of which are approved in multiple markets to aid in opioid use disorder management.

Indivior was established in 2014 through a demerger from the pharmaceuticals division of Reckitt Benckiser Group plc, inheriting decades of research and commercial expertise in addiction medicine.